Gemcitabine

Generic Name: Gemcitabine

Brand Names: Gemzar

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₁F_₂N_₃O_₄

CAS Number: 95058-81-4

Unique Ingredient Identifier: B76N6SBZ8R

Background: Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...

Indication: Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.

In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...

Associated Conditions: Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Phase 3

Recruiting

Conditions: Urothelial Carcinoma

Interventions: Drug: gemcitabine
Drug: disitamab vedotin
Drug: pembrolizumab
Drug: cisplatin
Drug: carboplatin

First Posted Date: 2023-06-22

Last Posted Date: 2024-11-13

Lead Sponsor: Seagen Inc.

Target Recruit Count: 700

Registration Number: NCT05911295

Locations: 🇺🇸
Inova Schar Cancer Institute, Fairfax, Virginia, United States
🇧🇷
Hospital de Cancer de Barretos - Fundacao Pio XII, Barretos, Other, Brazil
🇧🇷
Centro de Oncologia da Bahia, Salvador, Other, Brazil

and more 113 locations

Canagliflozin With Gemcitabine in Pancreatic Carcinoma

Not Applicable

Not yet recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Canagliflozin and Gemcitabine
Drug: Gemcitabine

First Posted Date: 2023-06-15

Last Posted Date: 2023-06-15

Lead Sponsor: Zhang Xiaofeng,MD

Target Recruit Count: 20

Registration Number: NCT05903703

Locations: 🇨🇳
Hangzhou first people's Hospital, Hangzhou, Zhejiang, China

Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 1

Not yet recruiting

Conditions: Nasopharyngeal Carcinoma
Immune Checkpoint Inhibitors

Interventions: Drug: Cadonilimab
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2023-06-12

Last Posted Date: 2023-06-12

Lead Sponsor: Guangxi Medical University

Target Recruit Count: 20

Registration Number: NCT05898256

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Phase 2

Recruiting

Conditions: Ovarian Cancer
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
Platinum-resistant Ovarian Cancer

Interventions: Drug: Gemcitabine
Drug: Luveltamab tazevibulin
Drug: Pegfilgrastim
Drug: Paclitaxel
Drug: Pegylated liposomal doxorubicin
Drug: Topotecan

First Posted Date: 2023-05-23

Last Posted Date: 2024-08-29

Lead Sponsor: Sutro Biopharma, Inc.

Target Recruit Count: 600

Registration Number: NCT05870748

Locations: 🇺🇸
Texas Oncology, Dallas, Texas, United States
🇺🇸
Ohio State University Center, Columbus, Ohio, United States
🇺🇸
Baptist Health South Florida (BHSF) - Miami Cancer Institute, Miami, Florida, United States

and more 36 locations

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Metastatic Solid Tumor
Non-small Cell Lung Cancer
Gastric Cancer
Pancreatic Ductal Adenocarcinoma

Interventions: Drug: RO7496353
Drug: Capecitabine
Drug: Atezolizumab
Drug: Nab-paclitaxel
Drug: S-1
Drug: Gemcitabine
Drug: Nivolumab
Drug: Oxaliplatin

First Posted Date: 2023-05-19

Last Posted Date: 2024-12-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 102

Registration Number: NCT05867121

Locations: 🇺🇸
UCLA University of California Los Angeles, Los Angeles, California, United States
🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

and more 26 locations

GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer

Phase 2

Recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Losartan
Drug: Gemcitabine
Drug: Nab paclitaxel
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2023-05-16

Last Posted Date: 2024-01-05

Lead Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Target Recruit Count: 34

Registration Number: NCT05861336

Locations: 🇮🇹
UO Oncologia, AUSL della Romagna, Ravenna, Italy
🇮🇹
U.O. Radioterapia IRCCS IRST, Meldola, Forlì, Italy

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

Phase 2

Recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: AK104
Drug: Gemcitabine
Drug: Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin
Drug: Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate
Drug: Nab-Paclitaxel

First Posted Date: 2023-05-16

Last Posted Date: 2024-12-16

Lead Sponsor: Akeso

Target Recruit Count: 78

Registration Number: NCT05859750

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳
Union Hospital Tongji Medical College Huazhong University of Science And Technology, Wuhan, Hubei, China

and more 4 locations